Given the plethora of diseases in which complement is activated, the complement cascade presents a tough challenge for drug discovery. The reported diversity in involved components and pathways, affected organs, time courses, and case numbers for different diseases renders a “one-size-fits-all” complement treatment virtually impossible and suggests that therapeutic concepts have to be tailored to specific disorders.
This means that a biomarker strategy must be integrated into various phases of complement therapeutic drug development, from early discovery to late clinical drug development. Like drug candidates in general, complement inhibitors have seen a shift from small molecules to large biopharmaceuticals such as proteins, antibodies and peptides, though this trend seems to be much more pronounced for complement-related drugs.
With the potential to inhibit a specific enzyme, prevent protein/protein interactions or interfere with conformational transitions, local and ‘targeted’ inhibition of complement activity has been the driver behind many innovative drugs that deliver therapy to tissues.
As the complement cascade offers several interconnectivities and bypasses to the traditional complement activation pathways at almost any level ranging from initiation and primary activation to amplification, effector signaling, and lysis, there is a need for robust, validated, complement biomarkers to improve diagnosis, monitoring of drug activity and therapeutic response and to guide the development of safer and targeted therapies for various diseases.
As complement therapeutics become more widely used, the discovery and development of disease-related biomarkers will assist in optimal decision-making throughout the course of drug development and improve our understanding of the disease processes.
Effective translation of the preclinical biomarkers into the clinic will pave the way towards effective execution of personalized therapies across complex disease areas for the benefit of patients, healthcare providers and the biopharmaceutical industry.
Svar has over 15 years’ experience of complement system assay development. Our complement system assays have been developed by our experienced scientists in close collaboration with key opinion leaders, to yield sensitive, reliable and easy-to-use products for the exploration of most aspects of the complement system.
The Svar Complement activity biomarkers give valuable intelligence in several situations where one might suspect that complement activation plays a role in the disorder. They are developed to target the unique neoepitopes only presented at the complement component or complex when activated.
Take advantage of our complement expertise and let us guide you on the Complement Pathway!